Skip to main content
. 2020 Oct 18;202(2):162–192. doi: 10.1111/cei.13517
What is the best type of protection?
Is sterilizing immunity the only approach or would disease reduction, without altering disease transmission work?
How to achieve equitable global distribution?
Is human challenge part of the pathway to a licensed product?
What is the risk of immunopathology?
How long will protection last after natural infection or vaccination?
Can better immunogenicity be achieved with vaccination than after natural infection?